Montanaro Asset Management Ltd, a premier investment firm based out of London, has recently increased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by a staggering 17.3%. This news, reported in its most recent 13F filing with the Securities and Exchange Commission (SEC), sheds light on Montanaro Asset Management’s savvy investment decisions and intuitive forecasting abilities.
Axon Enterprise, Inc. is a biotechnology company that is revolutionizing personal defense through the development, manufacture, and sale of conducted electrical weapons designed to provide everyday citizens with heightened safety measures. As a result of their innovative products and services backed by extensive research, Axon Enterprise has found success in both its TASER segment as well as Software and Sensors segment.
Shares of NASDAQ:AXON opened at $219.91 on Friday with a 50-day simple moving average sitting slightly lower at $219.26 while the two-hundred day simple moving average rests at $192.72. Despite this disparity between averages, both Montanaro Asset Management Ltd and Axon Enterprise have been performing phenomenally well on the stock market with consistent upward momentum reflective in their financials.
The investment firm now boasts ownership over an impressive 31,150 shares of Axon Enterprise worth an extraordinary $5,169,000 at the close of last quarter alone. The increase comes after Montanaro Asset Management Ltd executed several strategic transactions allowing for increasing margins without jeopardizing portfolio diversity or stability.
As we head into 2021 building on last year’s exponential growth for biotech companies like Axon Ventures (NASDAQ: AXON), investors are paying close attention to how these companies will fare despite economic decline brought on by COVID-19 concerns.
All factors considered – the rise in stake through successive quarters signals Montanaro Asset Management’s investment prowess alongside vast knowledge about up-and-coming markets through disciplined assessment techniques that consider scientific advancement, capital, and geopolitical economic trends.
Axon Enterprise: Recent Share Activity and Analyst Reports
Axon Enterprise: A Look at Recent Share Activity and Analyst Reports
Axon Enterprise, a biotechnology company that develops products for law enforcement agencies, has recently attracted the attention of several institutional investors. U.S. Capital Wealth Advisors LLC acquired a new stake in Axon Enterprise during the fourth quarter worth around $29,000. North Star Investment Management Corp. also bought a position at around $41,000, while Accurate Wealth Management LLC followed at $49,000. Harvest Fund Management Co. Ltd raised its stake in shares of the company by 297% in the fourth quarter for a total of $70,000. Overall, institutional investors own 75.62% of the company’s stock.
In other news, Director Mark W. Kroll sold over 3,500 shares of Axon Enterprise’s stock on Tuesday, March 7th for an average price of $220.73 per share. This brings his total number of shares to around 10,142 valued at approximately $2,238,643.
Among various reports issued recently on AXON shares is an “overweight” rating from Barclays with a price target increase from $177 to $222 based on their latest report from Thursday March 2nd – proving highly beneficial results for shareholders since then. Additionally initiated coverage on AXON was StockNews.com with a hold rating on March 16th giving insight and advice to potential investors looking into acquiring or holding onto Axon Enterprise stocks where they see fit.
Raymond James decreased its recommendation from “strong-buy” to “outperform” rating however others remained bullish with Craig Hallum increasing its price objective from $215 to $242 and Credit Suisse Group predicting even more growth with their prediction being raised from to $237-300 per share as well – clearly showing that Axon Enterprise’s location and technology based products are satisfying the market’s demands which bodes well for continued success.
In conclusion, Axon Enterprise’s recent surge in institutional investments along with favorable recommendations from leading analysts indicate the company’s continued growth is increasingly apparent, and just for the readers information; shares of the stock at close of trading last night were priced at $252.38.
